Treatment of congenital toxoplasmosis with pyrimethamine/sulfadiazine
- Conditions
- Congenital toxoplasmosis
- Registration Number
- JPRN-jRCTs071180093
- Lead Sponsor
- Maruyama Haruhiko
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 35
1. Confirmed toxoplasmosis fulfilling one of the followings
#1 Toxoplasma DNA detected in placenta or other tissues
#2 pathological identification of Toxoplasma
#3 anti-Toxoplasma IgM in cord blood or sera within 6 months after birth
#4 increase of anti-Toxoplasma IgG within 1 year after birth
#5 positive anti-Toxoplasma IgG after 12 months after birth
2. Suspected toxoplasmosis with all of the followings
#1 typical symptoms (e.g. intra-cranial calcification)
#2 positive anti-Toxoplasma IgG
#3 other congenital infections excluded
#1 HIV positive patients
#2 patients allergic to test compounds
#3 patients with megaloblastic anemia due to
folate deficiency
#4 No consent is given from the patient
him/herself nor a legally authorized
representative/guardian of the patient
#5 patients principal investigator judged
inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method